Galmed pharmaceuticals announces pricing of $7 million public offering

Tel aviv, israel , july 14, 2023 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "offering").
GLMD Ratings Summary
GLMD Quant Ranking